Risk Management



When FDA Leaves Doctors to Their Own Devices

By Kimberly Wittchow, JD

Ms. Wittchow is a staff attorney with OMIC’s Risk Management/Legal Department.

Digest, Spring 2003 

 

To view the two tables referenced in this article, go to the link http://www.omic.com/new/digest/DigestSpri_03.pdf

With the constant development of new devices in the global health care marketplace, ophthalmologists in the U.S. are privy to various treatment alternatives, many of which are tested and employed by their peers around the world long before they are approved for use in the U.S. What are the liability risks and risk management issues that arise if American doctors opt to use devices not yet approved by the Food and Drug Administration (FDA)?

Off-label use—the practice of using an FDA-approved drug or device for a purpose that the FDA has not approved—was explored in “Medicolegal Implications of Using Off-label Drugs and Devices,” (OMIC Digest, Winter 1996). The FDA states that doctors, in the exercise of their best judgment, may use approved drugs or devices off-label if they are well informed about the product, base its use on firm scientific rationale and sound medical evidence, and maintain records of its use and effects.

A related, riskier issue—the use of unapproved devices—was recently brought to OMIC’s attention by an insured who inquired about the soft tissue filler, Restylane, an injectable, gel-like substance containing hyaluronic acid that is currently used throughout Europe and Canada for lip augmentation and facial contouring. The FDA has received the results of US clinical trials of Restylane and is expected to approve it this summer (2003).

Compared to the FDA position on off-label use, the appropriateness of unapproved use is less clear. To understand the liability risks of using a device not approved by the FDA, it is necessary to understand the FDA device approval process. The Food, Drug and Cosmetic Act (FDCA) states that if a device is labeled, promoted or used in the US, it will be regulated by the FDA and is subject to pre-marketing and post-marketing regulatory controls to assure safety and effectiveness. Devices are broken down into three classes. Like collagen, Restylane, used for purposes similar to dermal collagen implants, is a Class III device (the most stringent regulatory category). Pre-market Approval (PMA) is the required process of scientific review to ensure the safety and effectiveness of Class III devices. Clinical trials using un- approved medical devices on human subjects are performed under an Investigational Device Exemption (IDE). They must be approved by the FDA and by an Institutional Review Board (IRB) before the study can begin. The IDE allows the device to be used in order to collect the safety and effectiveness data required to support the PMA application to the FDA. Ophthalmologists must be aware that gathering new information on multiple patients for publication purposes, or to obtain approval for a new device or new use of an approved device, probably constitutes research and will require an IDE. However, if the use is based on firm scientific rationale and sound medical evidence, it is probably the practice of medicine, which is theoretically unregulated.

While the FDA approves and regulates the production, sale, and clinical research of medical devices, it does not directly regulate the practice of medicine. OMIC’s recent inquiries of FDA staff in the ophthalmic devices division reiterated this posi- tion. However, some courts will look for exceptions to a completely “hands off” position. For instance, the Pennsylvania Superior Court held that since the FDA had never approved the use of liquid silicone injections, the trial court erred when it gave a jury the instruction that the FDA has no authority to regulate the practice of medicine. The court noted that this instruction gave the jury the incorrect impression that a physician “can use any drug he wants, irrespective of whether it has been approved or disapproved by the FDA.”

Whether the FDA can or will regulate physicians using unapproved devices may be less important than the consequences resulting when a physician uses such a device to treat a patient and the patient files a malpractice lawsuit or disciplinary action with a state licensing board. The crucial question then becomes whether the physician met the standard of care based upon what reasonable physicians in the same specialty would do at the same time under similar circumstances.

Case law has shown that violating the FDCA may be evidence of a breach of the standard of care and consequently result in a determination that malpractice has occurred. A plaintiff attorney could argue that the use of an unapproved device constitutes negligence per se (negligence per se or legal negligence is negligence established as a matter of law, usually arising from a statutory violation). If state laws are stricter than the federal FDCA and specifically prohibit the use of unapproved devices, it would be easier for the plaintiff to prove a violation of the law and argue either negligence per se or breach of the standard of care.

In order to provide the best alterna- tive to the patient and stay one step ahead of the market competition, ophthalmologists may be tempted to offer the very latest in products or services. Before deciding whether to use the newest device available, several factors should be considered (see Questions to Ask Before Using a Non-FDA Approved Device). The analysis for non-FDA approved devices is based upon the same exer- cise of professional judgment that should be used in determining whether to use approved or off-label treatment alternatives. Physicians

should take special care before using a device for an elective cosmetic procedure. Defense attorneys postulate that juries more closely scrutinize the care of the physician when problems arise in an elective procedure, rather than in an emergency or life-saving procedure. A 2001 OMIC survey found that 73% of ophthalmologists polled believed that elective surgery patients are more likely than other patients to sue their surgeon. Given the higher risk that elective procedures pose, ophthalmologists should consider additional factors in order to make sound decisions to use non-FDA approved devices (see Additional Questions to Ask Before an Elective Cosmetic Procedure).

Applying this risk analysis to three different devices shows how fact- dependent the outcome of the analysis can be. First, in the case of Restylane, it appears that its use prior to FDA approval would be difficult to defend in a lawsuit. Even though physicians throughout Europe and Canada have been using Restylane with positive results since the mid-1990s, surgeons in the U.S. will need to gather data based on larger numbers of patients over extended periods of time in order to determine its long-term safety and efficacy. Patient expectations also will have a profound influence on the risk of using Restylane. Web sites already tout Restylane as a method that is “fast and safe and leaves no scars or other traces on the face.” Because the efficacy of Restylane is dependent on many variables, such as age, skin type, lifestyle, and muscle activity, patients with unrealistic expectations may be disappointed if they do not achieve the volume, smoothness, or long-lasting effects they anticipated. These factors create an especially risky environment in which to use a non-FDA approved device; prudent physicians would be well advised not to use Restylane (outside of an approved clinical trial) until it is approved by the FDA. A disappointed patient and plaintiff attorney will not have to look hard for theories of liability or experts to support a lawsuit against an ophthalmologist who injects this “unproven” material.

The second device group assessed for use prior to FDA approval is cap- sular tension rings, Class III devices marketed by Morcher and Ophtec and currently undergoing pre-market approval review with the FDA. These devices are being used in cataract surgery with some regularity and ophthalmologists are sharing their results with their peers. Because these devices are being used therapeutically for medical treatment, some of the patient expectation variables that arise in cosmetic pro- cedures are avoided. Nevertheless, because they are relatively new to the market, ophthalmologists should use them with caution.

The final example is cyanoacrylate adhesive, used by ophthalmologists for the medical treatment of corneal perforations. One variant of this product, Dermabond Topical Skin Adhesive (2-octyl cyanoacrylate), was approved by the FDA in 2002 to seal out infection-causing bacteria. Yet cyanoacrylate adhesives have been used in the US for wound repair as an alternative to sutures since the Vietnam War in the mid- 1960s. Even before Dermabond’s FDA approval, variations of this adhesive had a long and proven track record and near universal acceptance in the ophthalmic community. Because of its wide-spread peer use and longevity, ophthalmic use of cyanoacrylate adhesive for the treatment of small perforations or leaks would most likely be considered standard medical practice in the community even when applying the most conservative analysis criteria.

After review, if the ophthalmologist decides that there is sound medical evidence and it is in the patient’s best interest to use a non-FDA approved device, he or she should conduct and document a thorough and careful informed consent discussion. The patient should be informed of the nature of the technique or device being used, its scientific basis, its benefits, and any possible drawbacks or criticisms from other practitioners. Especially with cosmetic procedures, other options should be discussed, and the patient should be encouraged to seek a second opinion before proceeding.

If the unapproved device in question is used under an IDE, the federal government requires that the physician have a special, detailed informed consent discussion with the patient which addresses its unapproved status. If the device is not being used under an IDE, physicians should consult with legal counsel about whether state law requires them to disclose the device’s unapproved status to the patient as part of the informed consent discussion. Regardless of state or federal law, from a risk management perspective, it is always advisable to respect the patient’s right to obtain the information needed to make reasoned decisions about his or her own health care. If the physician reasonably believes that the approval status of the device to be used in the patient’s treatment will be a factor in the patient’s decision to undergo the procedure, this information should be disclosed.

Finally, ophthalmologists should always check with the Underwriting Department of their professional liability carrier to ensure that they will be covered for any off-label or non-FDA approved procedure they are contemplating.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



boxes

Six reasons OMIC is the best choice for ophthalmologists in America.

#6. Supporting your specialty.

OMIC was founded by members of the American Academy of Ophthalmology nearly a quarter century ago and is the only carrier sponsored and endorsed by AAO. OMIC is also endorsed by 40 other ophthalmic societies. The OMIC partnerships with state and subspecialty societies qualifies their members for an exclusive 8% premium credit. Contact your state society for details.

61864684